Atara Biotherapeutics
Update in progressATRA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Atara Biotherapeutics develops transformative therapies for cancer and autoimmune diseases, in the U.S. and internationally. Its lead program, Tab-cel (tabelecleucel), is in Phase 3 for EBV-associated post-transplant lymphoproliferative disease and other EBV-driven conditions. It is also developing ATA3219, an allogeneic CD19 CAR-T for B-cell cancers and autoimmune diseases. Collaborations include MSK and QIMR. Founded in 2012, based in Thousand Oaks, CA.
Company score
- Sentiment
- -0.40
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.22
- Governance
- -0.31
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Anhco Nguyen Ph.D.
- Founded2012
- Employees10
- Websitewww.atarabio.com
Identifiers
- ISINUS0465131078
- FIGIBBG005Q3MQY4
- LEI549300WBXUXZRE03MS38
- CUSIP046513107
- CIK0001604464